Pfizer to Cease Vaccine Commercial Operations in China
This article is for subscribers only.
Pfizer Inc. is ceasing its vaccine commercial operations in China after the government failed to renew its license for a key shot for children, the latest sign of the uncertainties facing international drugmakers in the nation.
The Chinese import license for the Prevenar-brand vaccine expired last year, the U.S. pharmaceutical company said in a statement Thursday. It expects a shortage of the product in China before the launch of a newer version, called Prevenar 13, that it already sells in other parts of the world.